ramucirumab,pembrolizumab
eli lilly,merck
['pembro', 'ramucirumab']
plus pembrolizumab (rp) or investigator's choice standard of care (soc: docetaxel/ramucirumab, docetaxel, gemcitabine, and pemetrexed). use of rp was associated with significant overall survival compared to soc. doi: 10.1200/jco.22.00912
#asco22
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"